ILMN
What one share of Illumina holds
Laboratory Analytical Instruments
We are a global leader in sequencing- and array-based solutions for genetic and genomic analysis. Our products and services serve customers in a wide range of markets, enabling the adoption of genomic solutions in research and clinical settings.
Illumina’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-28; the balance sheet is as of 2026-06-28.
| Sales | $29.18 |
|---|---|
| Profit | $5.35 |
| Capex (buildings and equipment) | $1.06 |
| Free cash flow | $6.05 |
| Cash and investments | $6.89 |
| Debt | $13.19 |
| Book value | $18.79 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $16.20 | $3.13 | $1.76 | $3.51 | — | $15.05 |
| 2017 | $18.59 | $4.91 | $2.09 | $3.82 | — | $18.70 |
| 2018 | $22.37 | $5.54 | $1.99 | $5.68 | — | $25.56 |
| 2019 | $23.78 | $6.72 | $1.40 | $5.65 | — | $31.38 |
| 2020 | $21.89 | $4.46 | $1.28 | $6.02 | — | $32.15 |
| 2021 | $29.97 | $5.05 | $1.38 | $2.23 | — | $68.41 |
| 2022 | $29.20 | −$28.05 | $1.82 | $0.68 | — | $41.77 |
| 2023 | $28.51 | −$7.35 | $1.23 | $1.79 | — | $36.13 |
| 2024 | $27.50 | −$7.69 | $0.81 | $4.46 | — | $14.92 |
| 2025 | $27.84 | $5.45 | $0.95 | $5.97 | — | $17.80 |